Anima Research Center participating in a trial for an investigational RSV vaccine
Belgium’s largest medical trial middle encourages continued participation in trials to judge investigational vaccines
Center presently recruiting for members in its medical trial for Moderna’s investigational RSV vaccine
Alken, Belgium – September 15, 2022: One of Europe’s main medical trial facilities, Anima Research Center, based mostly in Alken, Belgium, is asking on the Belgian public to proceed its help of investigational research, particularly these targeted on investigational vaccines that will probably fight winter viruses. Anima, which has grown since 2018 to develop into one of the profitable medical trial centres in Europe, needs to make sure that the excellent help for investigational drug and vaccine analysis continues, particularly as winter closes in and seasonal flu and viruses begin spreading.
Viruses that may trigger points in winter embrace Respiratory Syncytial Virus or RSV, a extremely infectious sickness that may trigger severe respiratory points akin to pneumonia and even dying in the aged and really younger. Over 160,000 folks globally die of RSV yearly and in Belgium alone, round 7,000 persons are recognized with it every year. There are presently no permitted vaccines or therapies for RSV, and Anima not too long ago partnered with US biotech firm Moderna to judge an investigational RSV vaccine, aimed on the over 60s.
Anima Research Center is the most important medical trial middle in Belgium. CEO and Principal Investigator, Dr Erik Buntinx, based the centre along with his spouse, Dr Hilde Bollen, and his daughter, Linde Buntinx, PhD. Since 2018, Erik and his household, together with a extremely skilled crew, have constructed Anima into a main European website for medical trials, specializing in trials for CNS issues and vaccines.
Dr Erik Buntinx, CEO of Anima Research Center and Principal Investigator, says: “RSV in most people will present as nothing more than a mild cold, however RSV in the elderly and very young can be very dangerous indeed. Despite huge amounts of research a vaccine has so far eluded developers, but we’re pleased to be supporting Moderna to recruit for their trial to evaluate an investigational vaccine. I would like to urge people to sign up if they are eligible – your contribution will help towards advancing research of an investigational vaccine to see if it is effective at preventing RSV.”
To learn extra concerning the trial and verify your eligibility, go to the Anima Research web site: https://www.animaresearch.com/en/study/respiratoir-syncytieel-virus-rsv/
– END –
For extra info, please contact:
Anima Research Center
Dr Erik Buntinx, CEO and Principal Investigator
Tel: + 32 11 94 91 15
Consilium Strategic Communications
Amber Fennell, Tracy Cheung, Maya Bennison
Email: [email protected]
Tel: +44 (0)20 3709 5813
About RSV
RSV is a extremely contagious virus that may have an effect on anybody and in gentle circumstances resembles the frequent chilly. But RSV also can trigger extra severe respiratory sickness, primarily in older adults and younger infants. RSV, like influenza (flu), is seasonal and in temperate climates usually happens through the winter months. RSV and influenza are totally different viruses; subsequently, even you probably have been vaccinated in opposition to the flu, you might get an RSV an infection.
About Anima Research Center
ANIMA Research Center (ARC) in Alken, Belgium, is a extremely specialised medical analysis middle and has been conducting medical research for greater than 25 years to check new medicine with a give attention to the central nervous system. Since 2018, ARC can be one of many largest check facilities in the world for vaccines and different preventive therapy strategies. Visit our web site to be taught extra: www.animaresearch.com
